The Pharma Data

JANUARY 13, 2021

TNX-1500 is a third generation anti-CD40-ligand mAb that has been designed by protein engineering to decrease Fc?RII Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering.

Pharmaceuticals 52

Pharmaceuticals Small Molecule Vaccine Protein Expression 52

Precision for Medicine

JUNE 26, 2023

Our partnerships are with the most innovative organizations, utilizing the most advanced, cutting-edge technologies and providing us with unparalleled experience in manufacturing small molecule, biologics and next-generation medicines,” said John Khoury, Executive Vice President at Project Farma. Bethesda, Md.,

Science 40

Science Small Molecule Clinical Research Engineering 40

LifeSciVC

APRIL 27, 2023

Three best-in-class molecules in the clinic, over $400 million invested and over $4 billion returned to equity holders, all while focused on our mission to design breakthrough medicines for patients. In those respects, one might look at Nimbus’ first chapter as a failure, but they’d be wrong.

Small Molecule 40

Small Molecule Computational Chemistry Engineering Clinical Development 40

The Pharma Data

OCTOBER 19, 2020

The appointments of Maarten and Teun come at an essential time for AM-Pharma as we finalize all preparations to move into the last stage of clinical development for our lead program,” said Erik van den Berg , Chief Executive Officer at AM-Pharma. Kenilworth, N.J., USA) from the period of 2006 to 2016.

Trials 40

Trials Small Molecule Cell Biology Clinical Trials 40

The Pharma Data

OCTOBER 26, 2020

These mAbs are already of human origin and functionally optimized for high potency by the donor’s immune system; hence, they technically do not require genetic engineering or further optimization to achieve full functionality. The Company’s pipeline is highlighted below: Aridis’ Pipeline. AR-301 (VAP). AR-101 (HAP).

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

The Pharma Data

JANUARY 19, 2021

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression.

Small Molecule 40

Small Molecule Clinical Development Treatment Disease 40

Alta Sciences

APRIL 17, 2024

Future generations of therapeutic agents that build on the success of ADCs include immune-stimulating antibody conjugates, engineered toxin bodies, and radioligand conjugates that aim to improve the therapeutic index while minimizing toxicity. Asia, and Europe.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52

The Pharma Data

OCTOBER 14, 2020

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Horsepox and vaccinia are closely related orthopoxviruses that are believed to share a common ancestor. 2018) PLoS One.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

The Pharma Data

NOVEMBER 22, 2020

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.

Clinical Trials 52

Clinical Trials Licensing Licensing Trials 52

The Pharma Data

SEPTEMBER 8, 2020

Together, these nine companies have collectively developed more than 70 novel vaccines that have helped to eradicate some of the world’s most complex and deadly public health threats, underscoring their experience in clinical development and regulatory rigor, as well as their longstanding commitments to patient safety and public health.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

SEPTEMBER 8, 2020

Together, these nine companies have collectively developed more than 70 novel vaccines that have helped to eradicate some of the world’s most complex and deadly public health threats, underscoring their experience in clinical development and regulatory rigor, as well as their longstanding commitments to patient safety and public health.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

OCTOBER 28, 2020

Our R&D Engine continued to advance our Wave 1 pipeline, with 7 new regulatory filings anticipated within the next 12 months, and we expanded our cell therapy capabilities, both of which will help drive Takeda’s future growth. . billion to date. Press release ). Press release ). Press release ).

Therapies 40

Therapies Clinical Trials Pharmaceutical Companies Engineering 40

The Pharma Data

SEPTEMBER 15, 2020

With the depth and breadth of our current portfolio, the tremendous potential of our pipeline and scientific engine, and the power of our culture of innovation, we are poised to continue delivering meaningful value to patients by addressing some of the world’s most difficult health challenges.”. mg/dL reduction for placebo.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

Drug Target Review

FEBRUARY 11, 2025

Addressing the long timelines and high costs of drug development is therefore critical for the advancement of medical innovation. Clinical development failure may be due to an inability to demonstrate efficacy or sufficient safety. Drugs that were developed and commercialised 30+ years ago were relatively simple small molecules.

Drug Development 59

Drug Development Bioinformatics Drugs Small Molecule 59